We use cookies to deliver our online services. Details of the cookies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you agree to our use of cookies. To close this message click close.

Early benefit assessment and price negotiations subject to AMNOG – risks for original companies through parallel import", PharmaR, book 4 (March 2013)

March 2013



Loading data